Proteomics

Dataset Information

0

Novel epigenetic based differentiation therapy for Acute Myeloid Leukemia


ABSTRACT: We have identified and characterized two lysine (K) deacetylase inhibitors (DACi), CM-444 and CM-1758. These inhibitors demonstrate the ability to promote myeloid differentiation in all acute myeloid leukemia (AML) subtypes at low, non-cytotoxic doses, setting them apart from other commercially available histone deacetylase inhibitors (HDACi). Upon analysis of the acetylome following treatment with CM-444 and CM-1758, we observed modulation of non-histone proteins involved in the enhancer–promoter chromatin regulatory complex, including bromodomain proteins (BRDs). This acetylation is crucial for enhancing the expression of key transcription factors directly involved in the differentiation therapy induced by CM-444 and CM-1758 in AML. In summary, these compounds present promising potential as effective differentiation-based therapeutic agents across AML subtypes, offering a novel mechanism for the treatment of AML

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

DISEASE(S): Acute Leukemia

SUBMITTER: Fernando Garcia  

LAB HEAD: Fernando Garcia Martinez

PROVIDER: PXD050623 | Pride | 2024-06-03

REPOSITORIES: Pride

Dataset's files

Source:

Similar Datasets

2024-05-20 | GSE219230 | GEO
2024-05-21 | GSE268008 | GEO
2024-01-04 | GSE245122 | GEO
2020-01-23 | E-MTAB-7817 | biostudies-arrayexpress
2010-12-31 | E-GEOD-15032 | biostudies-arrayexpress
2020-11-27 | E-MTAB-8630 | biostudies-arrayexpress
2015-01-29 | E-GEOD-58789 | biostudies-arrayexpress
2015-07-03 | E-GEOD-64862 | biostudies-arrayexpress
2011-06-02 | E-MEXP-2746 | biostudies-arrayexpress
2016-03-27 | E-GEOD-77847 | biostudies-arrayexpress